Hepatitis B Virus Reactivation in Patients With HBV-Related Advanced Hepatocellular Carcinoma Undergoing Lenvatinib and Camrelizumab Treatment.

IF 2.5 4区医学 Q3 ONCOLOGY

Cancer Control Pub Date : 2025-01-01 DOI:10.1177/10732748241309046

Bi Sheng, Dong Wang, Jingjing Wang

{"title":"Hepatitis B Virus Reactivation in Patients With HBV-Related Advanced Hepatocellular Carcinoma Undergoing Lenvatinib and Camrelizumab Treatment.","authors":"Bi Sheng, Dong Wang, Jingjing Wang","doi":"10.1177/10732748241309046","DOIUrl":null,"url":null,"abstract":"Objective: This study aimed to evaluate hepatitis B virus (HBV) reactivation and its effect on tumor response and survival outcomes in patients with HBV-related advanced hepatocellular carcinoma (HCC) undergoing lenvatinib plus camrelizumab treatment.Methods: 216 patients with HBV-related advanced HCC receiving lenvatinib and camrelizumab were enrolled. Overall survival (OS), progression-free survival, and tumor response were evaluated. Univariate and multivariate analyses were performed to determine risk factors for HBV reactivation.Results: HBV reactivation occurred in 24 patients (11.1%). It was associated with poor survival and tumor response in these patients. Undetectable DNA levels, the absence of antiviral therapy, and high ALT levels were identified as vital risk factors for HBV reactivation. After receiving or adjusting the antiviral strategy, tumor response improved in patients with HBV reactivation.Conclusions: HBV reactivation could occur in patients with HBV-related HCC, treated with lenvatinib and camrelizumab, worsening tumor response and patient survival. Regular monitoring of the indicators of HBV infection and effective antiviral treatments are recommended for these patients to prevent severe complications.","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"32 ","pages":"10732748241309046"},"PeriodicalIF":2.5000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Control","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/10732748241309046","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: This study aimed to evaluate hepatitis B virus (HBV) reactivation and its effect on tumor response and survival outcomes in patients with HBV-related advanced hepatocellular carcinoma (HCC) undergoing lenvatinib plus camrelizumab treatment.

Methods: 216 patients with HBV-related advanced HCC receiving lenvatinib and camrelizumab were enrolled. Overall survival (OS), progression-free survival, and tumor response were evaluated. Univariate and multivariate analyses were performed to determine risk factors for HBV reactivation.

Results: HBV reactivation occurred in 24 patients (11.1%). It was associated with poor survival and tumor response in these patients. Undetectable DNA levels, the absence of antiviral therapy, and high ALT levels were identified as vital risk factors for HBV reactivation. After receiving or adjusting the antiviral strategy, tumor response improved in patients with HBV reactivation.

Conclusions: HBV reactivation could occur in patients with HBV-related HCC, treated with lenvatinib and camrelizumab, worsening tumor response and patient survival. Regular monitoring of the indicators of HBV infection and effective antiviral treatments are recommended for these patients to prevent severe complications.

查看原文本刊更多论文

接受Lenvatinib和Camrelizumab治疗的hbv相关晚期肝细胞癌患者的乙肝病毒再激活

目的：本研究旨在评估乙肝病毒（HBV）再激活及其对接受lenvatinib + camrelizumab治疗的HBV相关晚期肝细胞癌（HCC）患者肿瘤反应和生存结局的影响。方法：216例hbv相关晚期HCC患者接受lenvatinib和camrelizumab联合治疗。评估总生存期（OS）、无进展生存期和肿瘤反应。进行单因素和多因素分析以确定HBV再激活的危险因素。结果：24例（11.1%）患者发生HBV再激活。在这些患者中，它与较差的生存率和肿瘤反应有关。检测不到的DNA水平、缺乏抗病毒治疗和高ALT水平被确定为HBV再激活的重要危险因素。在接受或调整抗病毒策略后，HBV再激活患者的肿瘤反应得到改善。结论：HBV相关性HCC患者在lenvatinib和camrelizumab联合治疗后，可能发生HBV再激活，使肿瘤反应和患者生存期恶化。建议这些患者定期监测HBV感染指标并进行有效的抗病毒治疗，以防止严重并发症的发生。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancer Control ONCOLOGY-

CiteScore

3.80

自引率

0.00%

发文量

148

审稿时长

>12 weeks

期刊介绍： Cancer Control is a JCR-ranked, peer-reviewed open access journal whose mission is to advance the prevention, detection, diagnosis, treatment, and palliative care of cancer by enabling researchers, doctors, policymakers, and other healthcare professionals to freely share research along the cancer control continuum. Our vision is a world where gold-standard cancer care is the norm, not the exception.